This typically involves the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), in line with the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines. This evidence concerns the gene ACE and kidney disorder.